Anixa Biosciences Inc financial data

Symbol
ANIX on Nasdaq
Location
3150 Almaden Expressway, Suite 250, San Jose, CA
State of incorporation
DE
Fiscal year end
October 31
Former names
ITUS Corp (to 9/27/2018), COPYTELE INC (to 8/27/2014)
Latest financial report
10-K - Q3 2024 - Jan 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.19K % -26.1%
Debt-to-equity 9.4 % +36%
Return On Equity -58.6 % -50.4%
Return On Assets -53.3 % -46.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.2M shares +1.57%
Common Stock, Shares, Outstanding 32.2M shares +3.38%
Entity Public Float 90.6M USD -24.9%
Common Stock, Value, Issued 322K USD +3.54%
Weighted Average Number of Shares Outstanding, Basic 31.9K shares +2.96%
Weighted Average Number of Shares Outstanding, Diluted 31.9K shares +2.96%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 210K USD
Revenue from Contract with Customer, Excluding Assessed Tax 210K USD
Research and Development Expense 6.4M USD +34.1%
General and Administrative Expense 7.44M USD +18.2%
Costs and Expenses 13.8M USD +23.3%
Operating Income (Loss) -13.8M USD -25.6%
Net Income (Loss) Attributable to Parent -12.6M USD -28%
Earnings Per Share, Basic -0.39 USD/shares -21.9%
Earnings Per Share, Diluted -0.39 USD/shares -21.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.27M USD +38.9%
Cash, Cash Equivalents, and Short-term Investments 20.7M USD
Assets, Current 21.4M USD -15.8%
Operating Lease, Right-of-Use Asset 229K USD +38%
Assets 21.6M USD -15.4%
Accounts Payable, Current 525K USD +155%
Accrued Liabilities, Current 1.95M USD +9.94%
Liabilities, Current 2.5M USD +23.3%
Operating Lease, Liability, Noncurrent 203K USD +65%
Liabilities 2.7M USD +25.7%
Retained Earnings (Accumulated Deficit) -241M USD -5.5%
Stockholders' Equity Attributable to Parent 20M USD -17.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 18.9M USD -19.2%
Liabilities and Equity 21.6M USD -15.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.31M USD -16.1%
Net Cash Provided by (Used in) Financing Activities 2.26M USD
Net Cash Provided by (Used in) Investing Activities 129K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 32.2M shares +3.38%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 83K USD
Deferred Tax Assets, Valuation Allowance 34.5M USD +16.6%
Deferred Tax Assets, Gross 34.5M USD +16.6%
Operating Lease, Liability 232K USD +32.6%
Lessee, Operating Lease, Liability, to be Paid 312K USD +54.5%
Operating Lease, Liability, Current 29K USD -44.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 63K USD -10%
Lessee, Operating Lease, Liability, to be Paid, Year One 56K USD -16.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 80K USD +196%
Lessee, Operating Lease, Liability, to be Paid, Year Three 64K USD -1.54%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 19.9K shares 0%
Unrecognized Tax Benefits 4.84M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 66K USD
Additional Paid in Capital 260M USD +3.26%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 100 USD/shares 0%